AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19466746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 108
Study 19466746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 108
Study 16682725 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF) added to prophylactic antibiotics
Number of subjects: 0
Study 16682725 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotics alone
Number of subjects: 0
Study 15293487 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented physiotherapy input (double the amount of physiotherapy)
Number of subjects: 70
Study 15293487 — intervention group
Group type: COMPARATOR
Intervention: Normal physiotherapy input (control group)
Number of subjects: 70
Study 11763010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 20
Study 11763010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9504788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre optic phototherapy (Ohmeda Biliblanket device)
Number of subjects: 124
Study 9504788 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 124
Study 9504788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre optic phototherapy
Number of subjects: 124
Study 8031229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 355
Study 8031229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/d
Number of subjects: 355
Study 8031229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 355
Study 8031229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 2574627 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 240 mg
Number of subjects: 12
Study 2574627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2574627 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 12
Study 2574627 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 12
Study 4906702 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 32
Study 31382028 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression wire arthrodesis (n=8)
Number of subjects: 17
Study 31382028 — intervention group
Group type: COMPARATOR
Intervention: Intraosseous wiring arthrodesis (n=9)
Number of subjects: 17
Study 28808808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (modified Atkins diet)
Number of subjects: 45
Study 28808808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten free casein free diet (GFCF)
Number of subjects: 45
Study 28808808 — intervention group
Group type: COMPARATOR
Intervention: Balanced nutrition (control group)
Number of subjects: 45
Study 25280429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-160 mg/d)
Number of subjects: 1029
Study 23438101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g of omega-3 polyunsaturated fatty acids (PUFA) for 12 weeks
Number of subjects: 201
Study 23438101 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of metformin (Met) for 12 weeks
Number of subjects: 201
Study 21692897 — intervention group
Group type: COMPARATOR
Intervention: PVAI alone (group I)
Number of subjects: 98
Study 21692897 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAI plus CFAE ablation (group II)
Number of subjects: 98
Study 18431350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with low dose systemic heparin (Group C)
Number of subjects: 450
Study 18431350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with conventional dose systemic heparin (Group B)
Number of subjects: 450
Study 18431350 — intervention group
Group type: COMPARATOR
Intervention: Uncoated extracorporeal circulation with conventional dose systemic heparin (Group A)
Number of subjects: 450
Study 18431350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits and low dose systemic heparin
Number of subjects: 450
Study 18431350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits with conventional dose systemic heparin
Number of subjects: 450
Study 17060116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 51
Study 17060116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 51
Study 17060116 — intervention group
Group type: COMPARATOR
Intervention: Losartan and Atenolol
Number of subjects: 51
Study 12440653 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM Internet Hybrid curriculum
Number of subjects: 0
Study 12440653 — intervention group
Group type: COMPARATOR
Intervention: Traditional textbook-based learning
Number of subjects: 0
Study 10071998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10 microg) added to 1.5% lidocaine (45 mg hyperbaric)
Number of subjects: 78
Study 10071998 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine (45 mg hyperbaric) alone
Number of subjects: 78
Study 7706761 — intervention group
Group type: EXPERIMENTAL
Intervention: Single UV exposure with double the patient's minimal erythema dose
Number of subjects: 0
Study 7706761 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated, shielded half of the same nevus
Number of subjects: 0
Study 2341229 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 400 kcal/day for 8 weeks
Number of subjects: 15
Study 2341229 — intervention group
Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD) - 1200 kcal/day for 18 weeks
Number of subjects: 15
Study 2341229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 15
Study 7441622 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information about the study; 568 practitioners; 19.7% agreed to participate.
Number of subjects: 1176
Study 7441622 — intervention group
Group type: COMPARATOR
Intervention: Brief introduction to the study; 605 practitioners; 33.4% agreed to participate.
Number of subjects: 1176
Study 7441622 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reminders sent to two thirds of the doctors; remaining third did not receive reminders.
Number of subjects: 1176
Study 6094282 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tioconazole 6% vaginal ointment
Number of subjects: 40
Study 6094282 — intervention group
Group type: COMPARATOR
Intervention: Systemic ketoconazole (400 mg/day for 5 days)
Number of subjects: 40
Study 30560523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement technique with awards after dental care (G2)
Number of subjects: 306
Study 30560523 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 306
Study 29337023 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (n=22)
Number of subjects: 62
Study 29337023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise (n=20)
Number of subjects: 62
Study 29337023 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (n=20)
Number of subjects: 62
Study 27555197 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal dexmedetomidine (1 μg/kg) with caudal bupivacaine
Number of subjects: 75
Study 27555197 — intervention group
Group type: COMPARATOR
Intervention: IV dexmedetomidine (1 μg/kg)
Number of subjects: 75
Study 27555197 — intervention group
Group type: COMPARATOR
Intervention: IV saline (control group)
Number of subjects: 75
Study 25001159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal administration
Number of subjects: 876
Study 22585883 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring, weekly health coaching, and home titration of blood pressure medications (n = 129)
Number of subjects: 237
Study 22585883 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring and health coaching but no home titration (n = 108)
Number of subjects: 237
Study 22585883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of both arms
Number of subjects: 237
Study 19816218 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) exercise at 30 Hz and 3.5 mm amplitude
Number of subjects: 19
Study 19816218 — intervention group
Group type: COMPARATOR
Intervention: Sham group (S) performing the same exercises without vibration
Number of subjects: 19
Study 17567564 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up survey
Number of subjects: 700
Study 17567564 — intervention group
Group type: COMPARATOR
Intervention: Mail follow-up survey
Number of subjects: 700
Study 15615747 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited cataract surgery (approximately 4 weeks wait)
Number of subjects: 306
Study 15615747 — intervention group
Group type: COMPARATOR
Intervention: Routine cataract surgery (12 months wait)
Number of subjects: 306
Study 11826591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 0
Study 11826591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10068173 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain grade (CPG) measured by SF36 and Glasgow Pain Questionnaire
Number of subjects: 5036
Study 10068173 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain management addressing social and psychological well-being
Number of subjects: 5036
Study 7598089 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training for more than 5 months
Number of subjects: 0
Study 2401751 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg bid
Number of subjects: 10
Study 2401751 — intervention group
Group type: COMPARATOR
Intervention: Warfarin sodium 30 mg
Number of subjects: 10
Study 7004446 — intervention group
Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal polysaccharide vaccine
Number of subjects: 32
Study 7004446 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 32
Study 31574047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated CO2 vaginal laser therapy
Number of subjects: 69
Study 31574047 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estrogen cream
Number of subjects: 69
Study 31117729 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/AuNPs
Number of subjects: 0
Study 31117729 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection process
Number of subjects: 0
Study 31117729 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding experiments with synthetic DNA oligonucleotides
Number of subjects: 0
Study 30006390 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS (baby-led weaning)
Number of subjects: 206
Study 30006390 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study 27323792 — intervention group
Group type: EXPERIMENTAL
Intervention: Office visit intervention
Number of subjects: 489
Study 27323792 — intervention group
Group type: COMPARATOR
Intervention: Patient portal intervention
Number of subjects: 489
Study 25085017 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids only (Group A)
Number of subjects: 21
Study 25085017 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids and glucose (Group AG)
Number of subjects: 21
Study 25085017 — intervention group
Group type: COMPARATOR
Intervention: Neither amino acids nor glucose (Group C)
Number of subjects: 21
Study 22079554 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9193
Study 22079554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 9193
Study 22079554 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 9193
Study 21171669 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 25, 50, 100, 200, 400, or 600 mg once daily for 10 days
Number of subjects: 0
Study 21171669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21171669 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat
Number of subjects: 0
Study 17924869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 80 mg + Metformin 850 mg
Number of subjects: 681
Study 17924869 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 80 mg
Number of subjects: 681
Study 17924869 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg
Number of subjects: 681
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angle at 47 degrees
Number of subjects: 19
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angle at 90 degrees
Number of subjects: 19
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angle at 32 degrees
Number of subjects: 19
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angle at 47 degrees (constant-force test)
Number of subjects: 19
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt angle at 67 degrees (constant-force test)
Number of subjects: 19
Study 15661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonischemic exercise in inclined position
Number of subjects: 19
Study 15661836 — intervention group
Group type: COMPARATOR
Intervention: Graded or constant-force exercise with arterial flow eliminated
Number of subjects: 19
Study 14631587 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized allergenic extracts, starting with 0.07 bioequivalent units (BEU), increasing to a maintenance dose of 700 BEU at six months, applied twice a week.
Number of subjects: 54
Study 14631587 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only (Control group).
Number of subjects: 54
Study 10624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.09 mg/kg
Number of subjects: 60
Study 10624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.14 mg/kg
Number of subjects: 60
Study 10624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.19 mg/kg
Number of subjects: 60
Study 10624642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.01 mg/kg (priming dose)
Number of subjects: 60
Study 7770402 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (0.3 ml daily, 3075 anti-Xa IU)
Number of subjects: 295
Study 7770402 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (0.2 ml-5000 UI if bodyweight < 70 kg or 0.3 ml-7500 IU if bodyweight ≥ 70 kg, twice a day)
Number of subjects: 295
Study 2391575 — intervention group
Group type: EXPERIMENTAL
Intervention: REC group (resistive exercise circuit)
Number of subjects: 43
Study 2391575 — intervention group
Group type: COMPARATOR
Intervention: WT group (standard weight training and running)
Number of subjects: 43
Study 6907498 — intervention group
Group type: EXPERIMENTAL
Intervention: New foot supports
Number of subjects: 100
Study 6907498 — intervention group
Group type: COMPARATOR
Intervention: Metal stirrups
Number of subjects: 100
Study 30195178 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min of jogging at 'moderate' intensity
Number of subjects: 101
Study 30195178 — intervention group
Group type: COMPARATOR
Intervention: 15 min of relaxation/concentration (control condition)
Number of subjects: 101
Study 27080865 — intervention group
Group type: EXPERIMENTAL
Intervention: Relay Model intervention group
Number of subjects: 500
Study 27080865 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures control group
Number of subjects: 500
Study 25470694 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 343
Study 25470694 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed plus cisplatin or carboplatin)
Number of subjects: 343
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM)
Number of subjects: 19
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM)
Number of subjects: 19
Study 22130391 — intervention group
Group type: COMPARATOR
Intervention: CON (Control session)
Number of subjects: 19
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM) for ND
Number of subjects: 19
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM) for ND
Number of subjects: 19
Study 22130391 — intervention group
Group type: COMPARATOR
Intervention: CON (Control session) for ND
Number of subjects: 19
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM) for T2D
Number of subjects: 19
Study 22130391 — intervention group
Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM) for T2D
Number of subjects: 19
Study 22130391 — intervention group
Group type: COMPARATOR
Intervention: CON (Control session) for T2D
Number of subjects: 19
Study 20662912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution rinse for 60 seconds after exposure to hydrochloric acid (0.01 M, pH 2)
Number of subjects: 0
Study 20662912 — intervention group
Group type: COMPARATOR
Intervention: Deionized water rinse for 60 seconds after exposure to hydrochloric acid (0.01 M, pH 2)
Number of subjects: 0
Study 20662912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution rinse
Number of subjects: 0
Study 20662912 — intervention group
Group type: COMPARATOR
Intervention: Deionized water rinse
Number of subjects: 0
Study 20662912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rinses (sodium bicarbonate and deionized water)
Number of subjects: 0
Study 17971401 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of functional mitral regurgitation (MR)
Number of subjects: 279
Study 17971401 — intervention group
Group type: COMPARATOR
Intervention: Absence of functional mitral regurgitation (MR)
Number of subjects: 279
Study 17971401 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional mitral regurgitation (MR)
Number of subjects: 279
Study 15968470 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 81
Study 15968470 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 81
Study 15968470 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and Propofol anesthesia
Number of subjects: 81
Study 12467132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of calcium + placebo
Number of subjects: 111
Study 12467132 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of amylomaize (19 g of resistant starch) + placebo
Number of subjects: 111
Study 12467132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 9825167 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization exercises with dilators (in vivo)
Number of subjects: 44
Study 9825167 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization exercises with dilators (in vitro)
Number of subjects: 44
Study 7988310 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lifestyle (Mexican Pimas)
Number of subjects: 35
Study 2728951 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent payment/frequent monitoring (n = 17)
Number of subjects: 47
Study 2728951 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent payment/frequent monitoring (n = 16)
Number of subjects: 47
Study 2728951 — intervention group
Group type: COMPARATOR
Intervention: Non‐contingent payment/infrequent monitoring (n = 14)
Number of subjects: 47
Study 27618789 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection plus integrated care (n=120)
Number of subjects: 225
Study 27618789 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC, n=105)
Number of subjects: 225
Study 26406164 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 201
Study 26406164 — intervention group
Group type: COMPARATOR
Intervention: Behavioral information
Number of subjects: 201
Study 24275006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 18
Study 24275006 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 18
Study 22795519 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRD‐4 GFR
Number of subjects: 188
Study 22795519 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 188
Study 22795519 — intervention group
Group type: COMPARATOR
Intervention: Classical cardiovascular risk factors
Number of subjects: 188
Study 21275162 — intervention group
Group type: EXPERIMENTAL
Intervention: Huatan Tongluo Granule (HTG)
Number of subjects: 66
Study 18165460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg/day)
Number of subjects: 114
Study 18165460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 15745936 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 15745936 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol-cyproterone acetate
Number of subjects: 35
Study 14746003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead isotope ratios from blood specimens
Number of subjects: 16
Study 14746003 — intervention group
Group type: COMPARATOR
Intervention: Lead isotope ratios from leaded gasoline
Number of subjects: 16
Study 10397416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic drug therapy
Number of subjects: 91
Study 10397416 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode-psychosis patients
Number of subjects: 91
Study 10397416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 9163067 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients (CD and UC)
Number of subjects: 100
Study 9163067 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 100
Study 8219952 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient testing for biochemical and bacteriological tests
Number of subjects: 12
Study 8219952 — intervention group
Group type: COMPARATOR
Intervention: Control (no near patient testing)
Number of subjects: 12
Study 8219952 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient testing for midstream urine analysis
Number of subjects: 12
Study 8219952 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient testing for cholesterol tests
Number of subjects: 12